Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Shorla Oncology

News headline image
Shorla Oncology® Announces U.S. FDA Approval of Larger Vial Size for Nelarabine Intravenous Administration for the Treatment of T-cell Acute Lymphoblastic Leukemia and T-cell Lymphoblastic Lymphoma
From Shorla Oncology
Via Business Wire
News headline image
Shorla Oncology Announces FDA Orphan Drug Designation for SH-110 to Treat Rare Brain Cancer Using Oral Liquid
From Shorla Oncology
Via Business Wire
News headline image
Shorla Oncology Announces FDA Approval of TEPYLUTE® 100mg, First and Only Ready-to-Dilute Multi-Dose Vial of Thiotepa to Treat Breast and Ovarian Cancer and Commercial Launch of TEPYLUTE 15mg and 100mg Vials in the U.S.
From Shorla Oncology
Via Business Wire
News headline image
Shorla Oncology Announces Expansion of U.S. Commercial Footprint with Launch of Dedicated Sales Force and Market Access Teams
From Shorla Oncology
Via Business Wire
News headline image
Shorla Oncology Announces FDA Approval of IMKELDI (imatinib) Oral Solution, an Oral Liquid for the Treatment of Certain Forms of Leukemia and Other Cancers
From Shorla Oncology
Via Business Wire
News headline image
Shorla Oncology Announces U.S. Food and Drug Administration (FDA) Expanded Approval of JYLAMVO™ (methotrexate), an Oncology and Autoimmune Drug for Pediatric Indications
From Shorla Oncology
Via Business Wire
News headline image
Shorla Oncology Announces FDA Approval for TEPYLUTE, A Novel Formulation to Treat Breast and Ovarian Cancer
From Shorla Oncology
Via Business Wire
News headline image
Shorla Oncology Announces FDA Filing Acceptance of New Drug Application to Treat Certain Forms of Leukemia and Other Cancers
From Shorla Oncology
Via Business Wire
News headline image
Shorla Oncology Announces FDA Filing Acceptance of New Drug Application for Novel Formulation to Treat Breast and Ovarian Cancer
From Shorla Oncology
Via Business Wire
News headline image
Shorla Oncology Welcomes Rayna Sethi Herman as Chief Commercial Officer
From Shorla Oncology
Via Business Wire
News headline image
Shorla Oncology Announces US Acquisition of Jylamvo, an Oncology and Autoimmune Drug from Therakind
From Shorla Oncology
Via Business Wire
News headline image
Shorla Oncology Secures $35M Series B Funding Round to Advance its Oncology Product Portfolio
From Shorla Oncology
Via Business Wire
News headline image
Shorla Oncology Announces Licensing Agreement and Strategic Partnership for Rights to Market Chemotherapy Drug, PIP-101, in the United States
From Shorla Oncology
Via Business Wire
News headline image
Shorla Oncology Announces U.S. FDA Approval of Nelarabine Injection for the Treatment of T-cell Leukemia
From Shorla Oncology
Via Business Wire
News headline image
Shorla Oncology Appoints Dennis Purcell as Chairman of the Board of Directors
From Shorla Oncology
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.